[go: up one dir, main page]

MX2010002765A - Derivado de 6-pirimidinil-pirimid-4-ona. - Google Patents

Derivado de 6-pirimidinil-pirimid-4-ona.

Info

Publication number
MX2010002765A
MX2010002765A MX2010002765A MX2010002765A MX2010002765A MX 2010002765 A MX2010002765 A MX 2010002765A MX 2010002765 A MX2010002765 A MX 2010002765A MX 2010002765 A MX2010002765 A MX 2010002765A MX 2010002765 A MX2010002765 A MX 2010002765A
Authority
MX
Mexico
Prior art keywords
pyrimid
pyrimidinyl
derivative
preventive
formula
Prior art date
Application number
MX2010002765A
Other languages
English (en)
Inventor
Kenji Fukunaga
Kazutoshi Watanabe
Pascal Barneoud
Jesus Benavides
Jeremy Pratt
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08290028A external-priority patent/EP2078717A1/en
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2010002765A publication Critical patent/MX2010002765A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto representado por la fórmula (I) o una sal farmacéuticamente aceptable de él: (ver fórmula (I)) que se usa para el tratamiento preventivo y/o terapéutico de una enfermedad provocada por la actividad anormal de la tau proteína cinasa 1 tal como enfermedades neurodegenerativas (por ejemplo, la enfermedad de Alzheimer).
MX2010002765A 2007-09-14 2008-09-12 Derivado de 6-pirimidinil-pirimid-4-ona. MX2010002765A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007269485 2007-09-14
JP2007275713 2007-09-25
EP08290028A EP2078717A1 (en) 2008-01-11 2008-01-11 6-Pyrimidinyl-pyrimid-2-one derivative
PCT/JP2008/066936 WO2009035162A1 (en) 2007-09-14 2008-09-12 6-pyrimidinyl-pyrimid-2-one derivative

Publications (1)

Publication Number Publication Date
MX2010002765A true MX2010002765A (es) 2010-05-19

Family

ID=39874051

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002765A MX2010002765A (es) 2007-09-14 2008-09-12 Derivado de 6-pirimidinil-pirimid-4-ona.

Country Status (15)

Country Link
US (2) US8198437B2 (es)
EP (1) EP2193129B1 (es)
JP (1) JP5249320B2 (es)
KR (1) KR20100074182A (es)
CN (1) CN101883770A (es)
AR (1) AR068439A1 (es)
AU (1) AU2008297817A1 (es)
BR (1) BRPI0816705A2 (es)
CA (1) CA2698819A1 (es)
EA (1) EA201070367A1 (es)
MX (1) MX2010002765A (es)
NZ (1) NZ584277A (es)
TW (1) TW200927134A (es)
WO (1) WO2009035162A1 (es)
ZA (1) ZA201002213B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
EP2193129B1 (en) 2007-09-14 2012-10-24 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-2-one derivative
TW201043618A (en) 2009-03-10 2010-12-16 Sanofi Aventis Intermediate compound for synthesizing pharmaceutical agent and production method thereof
EP2464632A1 (en) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
EP2464639A1 (en) * 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
IL160700A0 (en) * 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
DE60208051T2 (de) 2001-09-21 2006-06-22 Sanofi-Aventis 3-substituierte-4-pyrimidonderivate
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
TW200621760A (en) * 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
EP1805164B9 (en) * 2004-09-29 2011-09-07 Mitsubishi Tanabe Pharma Corporation 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
AR064660A1 (es) * 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
EP2193129B1 (en) 2007-09-14 2012-10-24 Mitsubishi Tanabe Pharma Corporation 6-pyrimidinyl-pyrimid-2-one derivative
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona

Also Published As

Publication number Publication date
WO2009035162A1 (en) 2009-03-19
AR068439A1 (es) 2009-11-18
EA201070367A1 (ru) 2010-08-30
EP2193129A1 (en) 2010-06-09
JP2010538969A (ja) 2010-12-16
US8518939B2 (en) 2013-08-27
CA2698819A1 (en) 2009-03-19
ZA201002213B (en) 2011-06-29
US8198437B2 (en) 2012-06-12
CN101883770A (zh) 2010-11-10
EP2193129B1 (en) 2012-10-24
US20110021773A1 (en) 2011-01-27
KR20100074182A (ko) 2010-07-01
BRPI0816705A2 (pt) 2015-03-17
AU2008297817A1 (en) 2009-03-19
TW200927134A (en) 2009-07-01
NZ584277A (en) 2011-11-25
JP5249320B2 (ja) 2013-07-31
US20120252812A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
MX2009006947A (es) Derivados de pirimidona 6-heterociclica 2-sustituida.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MX2010002765A (es) Derivado de 6-pirimidinil-pirimid-4-ona.
PH12014500326B1 (en) Heterocyclic derivative and pharmaceutical drug
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
MX2009004908A (es) Compuestos quimicos.
NO20052223L (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
WO2008130879A3 (en) Tetrahydroindole and tetrahydroindazole derivatives
AR068438A1 (es) Derivado de 6-pirimidinil-pirimid-2-ona
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2011159124A3 (ko) Ｉｎｔｅｒｌｅｕｋｉｎ-６ 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
EP2266969A3 (en) 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors
TW200621760A (en) 2-morpholino-4-pyrimidone compound
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
WO2007009723A3 (en) Azepane- or azocane-substituted pyrazoline derivatives, their preparation and use as medicaments
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
MX2010008706A (es) Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal